Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness
Read more at globenewswire.comSana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Barchart·08/10/2026 15:05:00
语音播报
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.